We'll get you caught up on all the news you missed at the year's biggest healthcare investor conference

We'll get you caught up on all the news you missed at the year's biggest healthcare investor conference

san francisco


Thousands of investors, Wall Street analysts, execs, and of course, journalists, converged on San Francisco last week for the biggest healthcare investor event of the year - the J.P. Morgan Healthcare Conference.

It can be overwhelming, not to mention overcrowded. This year, more than 9,000 people signed up, and 485-plus companies were on the schedule to present.

If you had a hard time keeping up, we've got you covered. Here's all of the most important news you might have missed while you were conferencing last week.

Read more: Everyone at JPMorgan's big healthcare investor conference is buzzing about BMS-Celgene, Amazon, and new hires


Pairing off

The biggest news of the week was Eli Lilly's $8 billion bid for cancer-drug maker Loxo Oncology, announced on Monday morning.

That deal followed the massive $74 billion Bristol-Myers Squibb bid for Celgene, announced the week before.

With drugmakers flush with cash, top executives at firms like Merck and Gilead signaled in presentations at the event that there may be more M&A to come.

Read more: A top investor who just made $470 million on buzzy biotech Loxo's $8 billion takeover told us where he might place his next bets

Partnering up

Sometimes, it's better to keep things casual. Lots of companies announced new partnerships last week. Here are some of the highlights:

  • Civica Rx, the nonprofit that's bringing hospitals together to make their own generic drugs, keeps adding more members.
  • The health clinic startup One Medical is joining forces with a big Seattle health system to expand the kinds of care it can provide to patients.
  • Sanofi and Regeneron announced that they restructured their cancer drug collaboration.
  • Gilead struck a deal worth up to $785 million with the Korean pharma company Yuhan to work on a drug for patients with the liver disease NASH.

Pfizer, meanwhile, has been using its Pfizer Ventures arm and a partnership with Bain Capital to pursue brain research, after the drugmaker itself pulled back from the field last year. We dug in to the strategy.

Drug Developments

The conference can be a prime time for companies to announce clinical trial results for their drugs. And we'll include some other medical-treatment developments here too:

  • Sage Therapeutics had perhaps the best news of the conference. The company's stock surged 43% after it published data showing a drug its developing can help relieve symptoms of postpartum depressions.
  • Pear Therapeutics got FDA approval for a prescription app that helps treat opioid use disorder.
  • Digital health is heating up. Omada Health, which long focused on diseases like diabetes and obesity, is expanding into treatments for psychological issues such as depression and anxiety.
  • Invitae is going direct-to-consumer. The genetic testing company said it'll let individuals buy its tests online, though a clinician will still be involved to help interpret the results.

Catching Up

It's always good to get the latest news from old friends. My favorite update came from CVS Health, which laid out how (after its merger with health insurer Aetna), the company plans to reshape healthcare.

We also caught up with Jessica Mega at Verily, who filled us in on what the Alphabet-linked life sciences company is up to, after it just raised a fresh $1 billion.

And Jordge Conde, a general partner at Andreessen Horowitz, explained why he's now seeking to invest in therapeutics.


Never miss out on healthcare news. Subscribe to Dispensed, our weekly newsletter on pharma, biotech, and healthcare.